Gene differential expression analysis also suggested a high level of PIK3CB expression in the high-CRS group, which provides a rationale or its application as a biomarker for the use of PI3Kβ inhibitors for some patients with BLCA. This evidence concerns the gene PIK3CB and bladder transitional cell carcinoma.